Vmbook Online ordering

Biotechnology

Sure, here's the requested information on Bind Therapeutics, Inc.:

Company Overview:

Bind Therapeutics, Inc. is a biotechnology organization that focuses on formulating medication for treating cancer and other unmet medical necessities. The organization was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Stock Information:

With ticker symbol BIND, Bind Therapeutics, Inc. is publicly traded on the NASDAQ stock exchange.

Key financial pointers:

Market Capitalization: $167.88 million

Price-to-Earnings Ratio (TTM): N/A

52-Week Range: $0.46 - $2.34

Earnings:

On May 13, 2022, Bind Therapeutics, Inc. announced financial results for the first quarter, ended March 31, 2022.

* Net loss: $4.6 million

* Net loss per share: $0.17

* Research and development (R&D) expenses: $2.5 million

* General and administrative (G&A) expenses: $2.1 million

Growth:

There isn't much information available on the company's growth as Bind Therapeutics is primarily a clinical-stage biotechnology organization that is still in the process of creating its medicines and has yet to commercialize its products.

I hope the information was helpful! I'll be glad to help if you need more information.